Grifols, S.A. (NASDAQ:GRFS) Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership lowered its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 18.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 363,933 shares of the biotechnology company's stock after selling 84,503 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 0.05% of Grifols worth $2,708,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in Grifols by 144.0% in the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company's stock worth $17,782,000 after purchasing an additional 1,181,959 shares during the period. Helikon Investments Ltd bought a new position in shares of Grifols in the 4th quarter worth about $580,000. Stifel Financial Corp bought a new position in shares of Grifols in the 3rd quarter worth about $1,043,000. Norges Bank acquired a new position in shares of Grifols in the 4th quarter valued at about $14,434,000. Finally, GAMMA Investing LLC grew its position in shares of Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after buying an additional 1,527 shares during the last quarter.

Grifols Stock Performance

GRFS traded up $0.06 during trading on Tuesday, reaching $7.06. 145,566 shares of the company were exchanged, compared to its average volume of 1,218,195. Grifols, S.A. has a 52 week low of $5.79 and a 52 week high of $9.96. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The firm has a 50 day moving average of $7.49 and a 200 day moving average of $7.86. The stock has a market cap of $4.85 billion, a P/E ratio of 6.03 and a beta of 0.41.

Analyst Ratings Changes

Separately, Morgan Stanley began coverage on Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating for the company.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.